CPK-850 is a gene therapy commercialized by Novartis, with a leading Phase II program in Retinitis Pigmentosa (Retinitis). According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of CPK-850’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for CPK-850 is expected to reach an annual total of $10 mn by 2039 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
CPK-850 Overview
CPK-850 is under development for the treatment of retinitis pigmentosa. It is administered by subretinal route. The therapeutic candidate comprises of a gene delivered by using a AAV8 (adeno-associated virus 8) vector. CPK-850 acts by targeting RLBP1 gene. It is a new molecular entity (NME).
Novartis Overview
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
The company reported revenues of (US Dollars) US$51,742 million for the fiscal year ended December 2022 (FY2022), a decrease of 2.1% over FY2021. In FY2022, the company’s operating margin was 17.8%, compared to an operating margin of 22.1% in FY2021. In FY2022, the company recorded a net margin of 13.4%, compared to a net margin of 45.4% in FY2021.
The company reported revenues of US$13,208 million for the first quarter ended March 2023, an increase of 1.6% over the previous quarter.
For a complete picture of CPK-850’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.